Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14580060 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL5375868 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL11491917 | 0.83 | ALDH1A1 (0.50) | ALDH1A1KMT2ALMNAMAPTGAA | |
| SCHEMBL14580059 | 0.83 | SLC6A9 (0.43) | ALDH1A1KMT2APOLBAPEX1CASP6 | |
| SCHEMBL14580057 | 0.81 | ALDH1A1 (0.40) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL14864864 | 0.81 | CTSB (0.42) | ALDH1A1KMT2ALMNAMAPTPOLB | |
| SCHEMBL77799 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL4013521 | 0.81 | CYP3A4 (0.46) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL5652989 | 0.78 | MAPT (0.45) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL13271888 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KMT2ALMNAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | CAPRARO HANS-GEORG | 2007-09-13 | — | — | US | disclosed |
| US-7183301-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2007-02-27 | — | — | US | disclosed |
| US-7183301-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2007-02-27 | — | — | US | disclosed |
| US-7160912-B2 | Heterocyclic compounds having antibacterial activity: process for their preparation and pharmaceutical compositions containing them | DR.REDDY'S LABORATORIES LTD. (IN) | 2007-01-09 | — | — | US | disclosed |
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-04 | — | — | US | disclosed |
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-04 | — | — | US | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004712-A1 | Salts of novel heterocyclic compounds having antibacterial activity | OXA1L, LSS, MRPL21 | ALDH1A1 1398/4885KMT2A 4439/4885LMNA 4052/4885 |
| US-20070213355-A1 | 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases | ABL1, PRKCA, PRKCQ | ALDH1A1 2948/4885KMT2A 760/4885LMNA 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.